ArticleeLife2017
Type III CRISPR-Cas systems can provide redundancy to counteract viral escape from type I systems.
Article in eLife, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 104 citations in OpenAlex.
- Identification and structure determination of a type III-Bv CRISPR complex that post-translationally modifies an associated toxin.Structure (London, England : 1993) · 2026Article
- Predicting functions of uncharacterized gene products from microbial communities.Nature biotechnology · 2026Article
- A CRISPR array orchestrates virulence and host response inMicrobiology spectrum · 2026Article
- Review
- The complexity of multiple CRISPR arrays in strains with (co-occurring) CRISPR systems.microLife · 2026Article
- The early injected genomic region determines sensitivity to Type I restriction-modification defence against Autographiviridae phages.Nucleic acids research · 2025Article
- Crosstalk between three CRISPR-Cas types enables primed type VI-A adaptation in Listeria seeligeri.Cell host & microbe · 2025Article
- A type III-associated Cas6 functions as a negative regulator of type I-B CRISPR-Cas system in Thermus thermophilus.Communications biology · 2025Article
- Evolutionary insights into provirus-encoded CRISPR-Cas systems in halophilic archaea.microLife · 2025Article
- Distinct horizontal transfer mechanisms for type I and type V CRISPR-associated transposons.Nature communications · 2024Article
- Bioinformatic analysis of type III CRISPR systems reveals key properties and new effector families.Nucleic acids research · 2024Article
- Characteristics and immune functions of the endogenous CRISPR-Cas systems in myxobacteria.mSystems · 2024Article
- Article
- Clustered Regularly Interspaced Short Palindromic Repeat/CRISPR-Associated Protein and Its Utility All at Sea: Status, Challenges, and Prospects.Microorganisms · 2024Review
- Phages are unrecognized players in the ecology of the oral pathogen Porphyromonas gingivalis.Microbiome · 2023Article
- Discovery of an Abundant Viral Genus in Polar Regions through the Isolation and Genomic Characterization of a New Virus againstApplied and environmental microbiology · 2023Article
- The biology and type I/III hybrid nature of type I-D CRISPR-Cas systems.The Biochemical journal · 2023Review
- Bacteriophage strategies for overcoming host antiviral immunity.Frontiers in microbiology · 2023Review
- CRISPR-Cas systems are widespread accessory elements across bacterial and archaeal plasmids.Nucleic acids research · 2022Article
- Different modes of spacer acquisition by the Staphylococcus epidermidis type III-A CRISPR-Cas system.Nucleic acids research · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
CRISPR-Cas-mediated defense utilizes information stored as spacers in CRISPR arrays to defend against genetic invaders. We define the mode of target interference and role in antiviral defense for two CRISPR-Cas systems in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.